Optometric Education Consultants
  • About OEC
  • Case Challenge
  • Conferences
    • Nashville 2023
    • Scottsdale 2024
    • Pittsburgh 2024
    • Sarasota 2024
    • Barcelona 2024
    • Disney Resort 2024
    • Quebec 2024
    • Nashville 2024
    • Mackinac Island Recap
    • Germany Recap
    • Orlando Recap
    • All Conference Recaps
  • Webinars
  • Enduring Learning
  • YouTube & Resources
Select Page

TQ Quiz | Updates and Innovations in Macular Degeneration (Mackinac 2023)

by Events@optometricedu.com | Aug 17, 2023 | 2023 Mackinac Island, TQ Courses | 0 comments

"*" indicates required fields

Hidden

Updates and Innovations in Macular Degeneration

Hidden
MM slash DD slash YYYY
Hidden
MM slash DD slash YYYY
Hidden
MM slash DD slash YYYY
Hidden
1. Patients who have a sibling with AMD have a ______ of developing AMD than those who have a parent with AMD.*
2. All of the following are things that are recommendations for all levels of AMD except:*
3. A patient with medium drusen and no AMD pigmentary abnormalities is classified as:*
4. A patient with geographic atrophy has ___ 10 year risk of progression for high risk category.*
5. What is the current FDA treatment for Geographic Atrophy?*
6. What percentage of patients with AMD will develop neovascular AMD:*
7. Which of the following is the most appropriate testing to monitor for conversion to wet AMD:*
8. Patients with geographic atrophy*
9. Which component of the original AREDS formula vitamin was removed in the AREDS 2 formula.*
10. The AREDS 2 ten year follow up study showed*
11. Vitamins and supplements*
12. All the following digital retina home monitoring tools are phone based except which:*
13. Per AOA treatment guidelines often should patients with early AMD without neovascularization be seen:*
14. There is currently FDA approved treatment which of the following:*
15. The current number one treatment for neovascular AMD is:*
16. Faricimab is dual mechanism treatment for neovascular AMD working as anti-VEGF and ____.*
17. What is the most appropriate timeline for Retina specialist referral for a new diagnosis of neovascular AMD?*
18. Which of the following types of treatments are currently in FDA trials for AMD:*
19. Patients with permanent or pending permanent vision loss would benefit from all of the following except:*
20. Links have been indicated between AMD and all of the following neurodegenerative diseases except:*

Personal Information

Name*
Address*

Payment Information

After 10/18/2023, pricing will increase to $30.
This course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30.
Paying Via Credit Card A Paypal account is not required to pay using the button below. To pay using a credit card, click the Paypal button below. A new window will appear and a button "Pay with Debit or Credit Card" is available at the bottom of that window for your convenience. 
Payment Method
American Express
Discover
MasterCard
Visa
Supported Credit Cards: American Express, Discover, MasterCard, Visa
Card Number
Expiration Date Security Code  
Hidden

Course Information (HIDDEN)

Hidden
Hidden
Hidden
Do not include ending backslash (aka no .com/)
Hidden

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Upcoming Conferences

Ready to get away this summer or fall. View our upcoming conferences and register today!

View Events

Case Challenges

Case Challenges

View our library of case challenges and share your comments or questions in the comment box below!

Learn More
For questions and more information, please contact us at events@optometricedu.com

Like and follow us on Facebook, Twitter, and Instagram for conference updates!

Subscribe For Event Updates

* indicates required